Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

Feuerstadt, Paul; Bunim, Ari; Garcia, Heriberto; Karlitz, Jordan J.; Massoumi, Hatef; Thosani, Amar; Pellecchia, Andrew; Wolkoff, Allan W.; Gaglio, Paul J.; Reinus, John F.

doi:10.1002/hep.23429

Cited by 60 publications

(55 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since genetic and sociocultural diversity might influence the outcomes of HCV treatment, any generalization from the abovementioned results should await confirmation by community-based studies in patients of other races. Indeed, studies in other minority populations have shown lower SVR rates after combination treatment in African American and Hispanic patients in comparison with patients of western European ancestry [15][16][17][18]. Moreover, Feuerstadt et al [18] have recently demonstrated consistently poorer SVR rates following combination treatment among African American (13.7% in genotype 1 and 66.7% in genotype 2/3) and Hispanic patients (10.9% in genotype 1 and 30.6% in genotype 2/3), probably as a result of suboptimal clinical care and different socioeconomic status.…”

Section: Discussionmentioning

confidence: 98%

“…Indeed, studies in other minority populations have shown lower SVR rates after combination treatment in African American and Hispanic patients in comparison with patients of western European ancestry [15][16][17][18]. Moreover, Feuerstadt et al [18] have recently demonstrated consistently poorer SVR rates following combination treatment among African American (13.7% in genotype 1 and 66.7% in genotype 2/3) and Hispanic patients (10.9% in genotype 1 and 30.6% in genotype 2/3), probably as a result of suboptimal clinical care and different socioeconomic status. Of note, the SVR rates attained in our cohort were higher than those reported in real-world setting trials in both African American and Hispanic populations [15][16][17][18] (Fig.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 98%

Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The final limitation relates to our inability to control for treated cases. However, recent data suggest that fewer than 5% of HCV-infected individuals obtain treatmentinduced viral clearance [24]. Similarly, because the estimated prevalence of HCV was based on the balance of incoming incident and out-going cases (data provided by the population registry), successfully treated patients would have been retained with the prevalence calculations.…”

Section: Discussionmentioning

confidence: 99%

A population-based study of the epidemiology of hepatitis C in a North American population

Uhanova

Tate

Tataryn

et al. 2012

Journal of Hepatology

View full text Add to dashboard Cite

“…Thus, boceprevir can be used in combination with pegIFN and RBV for treatment of HCV genotype 1 and HIV co-infection. Feuerstadt et al posit that HCV patients belonging to minority groups when treated with pegIFN and RBV combination therapy demonstrated SVR among 14% of the genotype 1 patients [37]. The decreased level of SVR rate in the minority population of the US suggested the need for novel treatment regimens due to lack of responsiveness among these patients for the tested regimen.…”

Section: Interleukin-28b (Il28b)mentioning

confidence: 99%

Aspects of interferons (IFNs) interfering with HCV-G1 response

Qattan¹

2015

Integr Mol Med

View full text Add to dashboard Cite

Majority of the HCV infections are caused by HCV genotype 1 having high resistance to anti-HCV therapy among the Western population. Standard interferon (IFN) along with pegylated-interferon (pegIFN) α 2a or 2b combination with or without ribavirin is currently the approved therapy for HCV infection. Several factors are related with antiviral reaction and stratified according to factors related with virus, host, and on-treatment. The objectives of this review included exploration of phenomenon of interaction between HCV and IFN-α signalling pathway in patients receiving treatment with RBV and IFN-α as a combination therapy for chronic HCV infection (CHC). Another important objective of this review was to demonstrate mutations associated with ISDR region to develop understanding of the controversies and the correlations in resistance through chronic HCV-G1; in comparison to Japanese and other studies. Changes in SNPs occurring within IL28B were also evaluated along with the examination of relation between drugs and mutation. A literature review was performed commencing after literature search. Pertinent literature was searched through electronic databases PubMed, Science Direct, ProQuest, and MEDLINE during the period 2010 to 2014. Manual searching of the grey literature and various websites was conducted to obtain epidemiological data of HCV. The standard treatment for HCV infection is RBV and pegIFN combination therapy. However, SVR is induced in 50% of the HCV genotype 1 infection patients. The results of IL28B genotyping studies revealed that there appear to be differences between the distributions of the polymorphisms in different populations infected with HCV. NS5A mutations to be connected with decreased reaction to IFN treatment among HCV patients with genotype 1. PegIFN can be administered along with RBV regardless of the genotype conferring polymorphism and mutations for the production of interferon. Conclusion: Standard treatment for HCV infection is combination therapy of RBV and pegIFN-α2a or -α2b. Mutations in the IL28B have to be considered prior to the administration of RBV and pegIFN therapy for treating HCV-G1 infection in patients. Clinical trials should evaluate the efficacy of RBV and pegIFN combination therapy for HCV-G1 infection.

show abstract

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

Cited by 60 publications

References 21 publications

Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C

Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C

A population-based study of the epidemiology of hepatitis C in a North American population

Aspects of interferons (IFNs) interfering with HCV-G1 response

Contact Info

Product

Resources

About